HCM Hutchison China Meditech Ltd Sponsored ADR

Chi-Med to Announce 2018 Half-Year Financial Results

Chi-Med to Announce 2018 Half-Year Financial Results

LONDON, June 29, 2018 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM:HCM) (Nasdaq:HCM) will be announcing its interim results for the six months ended June 30, 2018 on Friday, July 27, 2018 at 7:00 am British Summer Time (BST).

An analyst presentation will be held at 9:00 am BST (4:00 pm Hong Kong Time) on the same day at Citigate Dewe Rogerson, 3 London Wall Buildings, London, EC2M 5SY, UK, which will be webcast via the company website at .  The presentation will be available to download before the analyst presentation begins.

For North America based analysts and investors, Chi-Med will also host a conference call with Q&A at 9:00 am Eastern Daylight Time (2:00 pm BST).  

Details of the analyst presentation and conference call dial-in will be provided in the financial results announcement.  A replay will also be available on the website shortly after each event.

About Chi-Med

Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products.  Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1).  For more information, please visit: .

CONTACTS

Investor Enquiries 
Mark Lee, Senior Vice President,

Corporate Finance & Development
+852 2121 8200
  
U.K. & International Media Enquiries 
Anthony Carlisle,

Citigate Dewe Rogerson
+44 7973 611 888 (Mobile)

  
U.S. Based Media Enquiries 
Brad Miles, Solebury Trout+1 (917) 570 7340 (Mobile)

Susan Duffy, Solebury Trout+1 (917) 499 8887 (Mobile)

  
Investor Relations 
Xuan Yang, Solebury Trout+1 (415) 971 9412 (Mobile)

David Dible,

Citigate Dewe Rogerson  
+44 7967 566 919 (Mobile)

  
Panmure Gordon (UK) Limited 
Richard Gray / Andrew Potts+44 (20) 7886 2500
EN
29/06/2018

Underlying

Reports on Hutchison China Meditech Ltd Sponsored ADR

Franc Gregori ... (+2)
  • Franc Gregori
  • Lala Gregorek

Trinity Delta Lighthouse: HUTCHMED

Trinity Delta view: HUTCHMED’s sustainable profitability aim is underpinned by continued commercial and R&D execution. Geographic expansion ex-China, new indications for current China products, and potential new product approvals will support near-term growth, while M&A and/or in-licensing have a role in the mid-term. Accelerated investment in the highly attractive ATTC platform, which could address a wide range of oncology indications with sizeable market potential, should drive longer-term pro...

 PRESS RELEASE

Intended Retirement of Independent Non-executive Director and changes ...

Intended Retirement of Independent Non-executive Director and changes of composition of board committees HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Professor Mok Shu Kam, Tony has informed the Company that he would not seek re-election after retiring from the Board at the forthcoming annual general meeting of the Company to be held on May 12, 2026 (“AGM”). Professor Mok has served as an Independent Non-executive Director of the Company for more than eight ...

Carol Dou Xiao Qin ... (+2)
  • Carol Dou Xiao Qin
  • Sunny Chen

HUTCHMED (China) (13 HK): 2025: Results In Line, Sales Recovery To Con...

2025 results were in line. Total revenue declined 13% yoy, but Fruquintinib’s in-market sales rebounded significantly hoh driven by continuous overseas growth and positive impact from sales restructuring in China. It targets oncology/immunology revenue of US$330m-450m supported by continued sales recovery. Seeing smooth R&D progress, we expect a new wave of market approvals to fuel growth for HUTCHMED in the years ahead. Maintain BUY with a lower target price of HK$26.00 reflecting rising geopol...

Bella Lu Yifei ... (+10)
  • Bella Lu Yifei
  • Carol Dou Xiao Qin
  • Claire Wang Kelai
  • Gigi Cheuk
  • Joyce Chu
  • Julia Pan Mengyao
  • Kate Luang
  • Ken Lee
  • Sunny Chen
  • Tham Mun Hon

Greater China Daily: Friday, March 6, 2026

Top Stories Economics | China China set a 2026 GDP growth target of 4.5-5.0% yoy, in line with expectations, while maintaining a 4% fiscal deficit ratio. Fiscal policy remains the main growth driver, supported by Rmb4.4t in local government special bonds and Rmb1.3t in ultra-long treasury bonds, while monetary policy stays accommodative. Policy priorities focus on AI+, New Quality Productive Forces, industrial upgrading, and targeted consumption support, alongside welfare improvements and the g...

 PRESS RELEASE

HUTCHMED Reports 2025 Full Year Results and Business Updates

HUTCHMED Reports 2025 Full Year Results and Business Updates — Geographic expansion driving ex-China sales growth; indication expansions driving China sales growth — — $457 million net income, driven by profitable core operations and non-core disposal — — Rapidly progressing groundbreaking ATTC technology, a source of novel drug candidates with broad therapeutic potential — — Pursuing potential opportunities for partnering ATTC candidates with multinational pharmaceutical companies — HONG KONG and SHANGHAI and FLORHAM PARK, N.J. , March 05, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Li...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch